Skip to content Skip to footer
Loncastuximab Tesirine-Lpyl: Benefits, Reviews, Info, Side Effects!
Rx Details
Loncastuximab Tesirine-Lpyl
Lonca, Zynlonta
Loncastuximab Tesirine-Lpyl
Prescription
Drug
Drugs
Breakthrough Therapy
treatment of relapsed or refractory large B-cell lymphoma, targeted therapy, potential for improved outcomes in specific patient populations, antibody-drug conjugate mechanism, potential for reduced tumor burden
Abdominal Pain, Constipation, Cough, Decreased Appetite, Diarrhea, Dizziness, Fatigue, Fever, Headache, Insomnia, Low Blood Cell Counts, Musculoskeletal Pain, Nausea, Peripheral Edema, Rash, Shortness Of Breath, Vomiting
Loncastuximab tesirine-lpyl, marketed under the brand name Zynlonta, is a prescription medication used for the treatment of certain types of lymphoma. The dosage of this drug can vary based on individual patient factors, including the specific condition being treated, the patient’s body surface area, and their overall health status. The typical dosing regimen for loncastuximab tesirine-lpyl is as follows: – The recommended dose is 0.15 mg/kg administered as an intravenous infusion over 30 minutes on Day 1 of each 21-day cycle for the first 2 cycles. – For subsequent cycles, the dose is reduced to 0.075 mg/kg on Day 1 of each 21-day cycle. It’s important to note that dosing may be adjusted based on the patient’s response to treatment and any side effects experienced. Therefore, it is crucial for patients to follow their healthcare provider’s instructions and not to self-adjust the dosage. Always consult with a healthcare professional for the most accurate and personalized dosing information.
Diffuse large b-cell lymphoma
Safety profile of Loncastuximab Tesirine-Lpyl is generally favorable.
No interactions found
$10,000 – $15,000
$12,000

A Synopsis of

Loncastuximab Tesirine-Lpyl

Loncastuximab tesirine-lpyl is a novel antibody-drug conjugate that has shown promising results in the treatment of certain types of lymphoma. This medication works by targeting a specific protein found on the surface of cancer cells, delivering a potent chemotherapy drug directly to the cancer cells while minimizing damage to healthy cells.

Clinical trials have demonstrated that loncastuximab tesirine-lpyl can be effective in patients with relapsed or refractory diffuse large B-cell lymphoma, a type of non-Hodgkin lymphoma that can be difficult to treat. Patients who have not responded to other treatments may benefit from this targeted therapy, which has shown high response rates and durable remissions in some cases.

As with any medication, loncastuximab tesirine-lpyl does come with potential side effects. These can include fatigue, nausea, fever, and low blood cell counts. It is important for patients to discuss these potential side effects with their healthcare provider and to report any unusual symptoms or changes in their condition.

Overall, loncastuximab tesirine-lpyl represents a promising new option for patients with certain types of lymphoma. If you or a loved one has been diagnosed with relapsed or refractory diffuse large B-cell lymphoma, it may be worth discussing this medication with your healthcare provider to see if it could be a suitable treatment option for you. Remember, always follow your healthcare provider’s recommendations and guidelines when taking any medication.

RxDb Legal Disclaimer

The information provided on RxDB.net is for informational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional, such as a doctor or pharmacist, for any questions or concerns regarding your health, medications, or medical conditions. Reliance on any information provided on this website is solely at your own risk. RxDB.net does not provide medical or pharmaceutical services and is not liable for any decisions made based on the information contained herein.

PAGE LAST UPDATED

Health Education Through Aggregation

Sign up for the Rx Database Newsletter!
Menu
Questions?

Website By Foxco © 2025. All rights reserved.

0
Would love your thoughts, please comment.x
()
x
en_USEN